drugset / Trial / NCT06992232
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
Phase 2
Recruiting
144 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Peking University First Hospital · collabThe First Affiliated Hospital of Soochow University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This multi-center randomized controlled phase II trial was carried out in several hospitals in China to evaluate the efficacy and safety of radiotherapy or radical prostatectomy combined with intense androgen deprivation therapy for newly diagnosed metastatic prostate cancer.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2027-07-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Apalutamide | Small molecule | — | — |
| Background | Darolutamide | Other / unclassified | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |
| Background | Rezvilutamide | Small molecule | — | — |